Oncology

Bicara Therapeutics

visit site

Clinical-stage company developing bifunctional antibodies to target tumors and modulate the tumor microenvironment for treating cancer.

Red Tree Participation
Co-investor in seed round, co-led Series B, co-investor in Series C and IPO

Red Tree Board Member

Heath Lukatch, Ph.D. (pre-IPO)

 

IPO
Total Addressable Market
Red Tree Board Member(s)

Red Tree Board Member

Heath Lukatch, Ph.D. (pre-IPO)

 

Red Tree Participation
Co-investor in seed round, co-led Series B, co-investor in Series C and IPO
visit site

Bicara Therapeutics

Oncology
Total Addressable Market
Red Tree Board Member(s)

Red Tree Board Member

Heath Lukatch, Ph.D. (pre-IPO)

 

Red Tree Participation
Co-investor in seed round, co-led Series B, co-investor in Series C and IPO